Preclinical anti-tumor activity of antibody-targeted chemotherapy with CMC-544 (inotuzumab ozogamicin), a CD22-specific immunoconjugate of calicheamicin, compared with non-targeted combination chemotherapy with CVP or CHOP

Abstract

Preclinically, CMC-544 provides greater therapeutic benefit than CVP or CHOP against BCL xenografts. CMC-544 may also be co-administered with standard chemotherapeutic regimens in the treatment of B-NHL for superior anti-tumor activity.

Synthesis of a Covalent Epirubicin-(C3-amide)-Anti-HER2/neuImmunochemotherapeutic Utilizing a UV-Photoactivated Anthracycline Intermediate

“…7,[26][27][28][29][30]35,40 Discussion A small spectrum of molecular platforms has been applied to facilitate selective ''targeted'' delivery of a variety of biological agents and conventional chemotherapeutics that can exert significant cytotoxic anti-neoplastic properties. Biological agents utilized in this regard include various immunotoxin preparations synthesized to enhance selective ''targeted'' delivery of Pseudomonas exotoxin, 64 84 and monomethyl auristatin E. [86][87][88][89] Several different chemical characteristics of the anthracycline class of chemotherapeutics can be utilized to develop multiple molecular designs and synthesis strategies allowing their covalent incorporation into immunoglobulin fractions or receptor ligands applying a variety of organic chemistry reactions. One method entails the reaction of both the carbohydrate C 3 monoamine group of anthracyclines and the e-amine of lysine residues within the amino acid sequence of immunoglobulin with the aldehyde groups found in sodium periodate oxidized dextran.…”

The role of monoclonal antibodies in the treatment of lymphomas

“…CD22 is considered a good target for antibody-based therapy because it is expressed on the majority of B-lymphocytic malignancies and is not expressed on hematopoietic stem cells or memory B cells [69]. In animal studies, IO displayed greater singleagent activity compared with CVP or CHOP and had significant antitumor activity when co-administered with standard chemotherapeutic agents [70].…”

Drug Delivery Systems and Combination Therapy by Using Vinca Alkaloids

“…Drugs are often administered simultaneously as a cocktail or sequentially to maximize their therapeutic impact. [111] Vincristine combined with cyclophosphamide and prednisone is called CVP, which is used as a first-line therapy for follicular B-cell lymphoma. [111-114] A combination of cyclophosphamide, doxorubicin, vincristine, and prednisone, called CHOP, is used in front-line therapy to treat patients with either follicular or diffuse large B-cell lymphoma.…”

“…[111] Vincristine combined with cyclophosphamide and prednisone is called CVP, which is used as a first-line therapy for follicular B-cell lymphoma. [111-114] A combination of cyclophosphamide, doxorubicin, vincristine, and prednisone, called CHOP, is used in front-line therapy to treat patients with either follicular or diffuse large B-cell lymphoma. [111-114] Rituximab combined with CVP or CHOP creates another first-line treatment for patients with diffuse large B-cell lymphoma and follicular lymphoma.…”